Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Transcriptional Therapy With the DNA Demethylating Hydralazine and the HDAC Inhibitor Valproate Associated to Concomitant Cisplatin Chemoradiation in FIGO Stage III Cervical Cancer.

NCT00404326 is registered in ClinicalTrials.gov with National Institute of Cancerología as lead sponsor.

NCT NCT00404326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00404326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Transcriptional Therapy With the DNA Demethylating Hydralazine and the HDAC Inhibitor Valproate Associated to Concomitant Cisplatin Chemoradiation in FIGO Stage III Cervical Cancer.
Lead sponsor
National Institute of Cancerología
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
November 30, 2006
Enrollment
18
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer